Trials / Completed
CompletedNCT00451152
Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate for treatment of elevated IOP in patients with open-angle glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anecortave Acetate Sterile Suspension, 30 mg/mL | Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months. |
| OTHER | Anecortave Acetate Vehicle | Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months. |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2007-03-23
- Last updated
- 2012-11-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00451152. Inclusion in this directory is not an endorsement.